NASDAQ · ANNX
Healthcare · Biotechnology
$4.19
Up+$0.25 (+6.35%)
Updated Nov 4, 2026, 3:12 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ANNX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ANNX closed at $4.19 after 21 trading sessions, up 3.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $3.98 | $4.23 | $3.93 | $4.19 | 4.29M |
| Nov 2, 2026 | $4.06 | $4.08 | $3.90 | $3.94 | 2.28M |
| Oct 30, 2026 | $4.00 | $4.09 | $3.87 | $4.05 | 2.84M |
| Oct 29, 2026 | $4.04 | $4.1999 | $3.95 | $4.01 | 3.28M |
| Oct 28, 2026 | $3.78 | $4.05 | $3.716 | $4.04 | 4.01M |
| Oct 27, 2026 | $3.72 | $3.84 | $3.68 | $3.76 | 2.96M |
| Oct 26, 2026 | $3.80 | $3.86 | $3.66 | $3.70 | 2.65M |
| Oct 23, 2026 | $3.78 | $3.85 | $3.64 | $3.75 | 2.58M |
| Oct 22, 2026 | $3.85 | $3.97 | $3.78 | $3.81 | 3.67M |
| Oct 21, 2026 | $3.85 | $4.07 | $3.84 | $3.86 | 4.95M |
| Oct 20, 2026 | $4.02 | $4.059 | $3.78 | $3.83 | 6.37M |
| Oct 19, 2026 | $3.65 | $4.03 | $3.435 | $4.01 | 6.36M |
| Oct 16, 2026 | $3.60 | $3.61 | $3.355 | $3.41 | 5.24M |
| Oct 15, 2026 | $3.70 | $3.82 | $3.50 | $3.60 | 2.65M |
| Oct 14, 2026 | $3.79 | $3.85 | $3.66 | $3.67 | 4.04M |
| Oct 13, 2026 | $3.96 | $3.96 | $3.78 | $3.83 | 3.42M |
| Oct 12, 2026 | $4.02 | $4.055 | $3.95 | $3.96 | 1.93M |
| Oct 9, 2026 | $3.97 | $4.135 | $3.97 | $4.02 | 2.39M |
| Oct 8, 2026 | $3.99 | $4.035 | $3.855 | $4.00 | 3.21M |
| Oct 7, 2026 | $3.99 | $4.175 | $3.91 | $4.01 | 2.45M |
| Oct 6, 2026 | $4.21 | $4.26 | $4.01 | $4.03 | 2.7M |
The latest Smart Investors Daily articles mentioning ANNX.
Company
Market Activity
Research & News
ANNX research
Company profile and research snapshot.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2026 | JP Morgan | Overweight | — |
| Sep 1, 2026 | JP Morgan | Overweight | — |
| Aug 13, 2026 | Citizens | Market Perform | — |
| Jul 21, 2026 | Citizens | Market Underperform | — |
No generated briefing is available yet.
Benzinga · Oct 28, 2026
Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will
Benzinga · Oct 19, 2026
HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
Yahoo · Oct 16, 2026
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 7, 2026, in accordance with Nasdaq Listing Rule 5635
Benzinga · Sep 30, 2026
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $15.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANNX.
